Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2018

Most Important Clinical Trials in Vascular Medicine and Intervention in the Past 10 Years

Presenter: Jay S. Giri, Sahil A. Parikh

September 22, 2018

Presentation SCAD 2018

How should we design future SCAD trials?

Presenter: Karin H Humphries

September 08, 2018

Presentation ESC 2018

FUnctional Testing Underlying REvascularization The FUTURE trial

Presenter: Gilles Rioufol

August 26, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: Howard C. Herrmann, Allan Schwartz, Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: Howard C. Herrmann, Allan Schwartz, Nicolas M. Van Mieghem

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Presentation CIT 2018

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Presenter: Bo Xu

March 23, 2018

Advertisement

Most Important Clinical Trials in Vascular Medicine and Intervention in the Past 10 Years

How should we design future SCAD trials?

FUnctional Testing Underlying REvascularization The FUTURE trial

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

UK All-Comers

Evolut R Low-Risk

Partner 3 Low-Risk

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content